Clearmind licenses psychedelic compounds for mental disorders
Pharmaceutical Technology
APRIL 18, 2024
Clearmind Medicine has entered into a licensing agreement with Yissum to develop Generation 3.0 psychedelic compounds for mental disorders.
Biogen licenses a stroke drug from Japanese drugmaker TMS
Bio Pharma Dive
MAY 12, 2021
The drug, which Biogen had an option to license, is one of two in the biotech's pipeline for a condition that has had few new treatments developed.
Licensing 
246
246 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS
Pharmaceutical Technology
JANUARY 31, 2023
Gene therapy company uniQure has entered into a global licensing agreement with Apic Bio for APB-102 to treat patients with amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1). The post uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS appeared first on Pharmaceutical Technology.
Gene Therapy 277
277 
Kite and Daiichi Sankyo update cell therapy licensing agreement
Pharmaceutical Technology
DECEMBER 8, 2022
Under the prior deal, Daiichi Sankyo acquired exclusive rights for the development, manufacturing and commercialisation of Yescarta in Japan. The post Kite and Daiichi Sankyo update cell therapy licensing agreement appeared first on Pharmaceutical Technology. Subsequently, in the same year, Gilead Sciences acquired Kite.
Licensing 305
305 
Merck pays $250M to license Moderna cancer vaccine
Bio Pharma Dive
OCTOBER 12, 2022
The drugmaker’s decision to grab rights to the shot deepens its ties with the COVID-19 vaccine developer and comes weeks before a key data release.
Vaccine 324
324 
IDRx, a new biotech startup, raises $122M to develop better cancer drug combinations
Bio Pharma Dive
AUGUST 2, 2022
Founded by serial entrepreneur Alexis Borisy, the company comes equipped with two experimental medicines it licensed from Merck KGaA and Blueprint Medicines.
Licensing 315
315 
Bain Capital backs new biotech startup developing oral asthma drug
Bio Pharma Dive
JULY 12, 2022
Areteia Therapeutics will receive $350 million from Bain and others to advance a drug that was previously licensed to Biogen for testing as an ALS treatment.
Drugs 283
283 
How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing
Drug Patent Watch
DECEMBER 12, 2024
Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.
Licensing 96
96 
C4XD and AstraZeneca enter $402m deal to develop respiratory disease therapy
Pharmaceutical Technology
NOVEMBER 28, 2022
C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. The deal has been signed to develop the C4X NRF2 Activator programme for these ailments. This includes an upfront payment of $2m from AstraZeneca.
Development 264
264 
Hookipa partners with Roche for cancer immunotherapy development
Pharmaceutical Technology
OCTOBER 21, 2022
Hookipa Pharma and Roche have signed a strategic partnership and licence agreement for developing HB-700 and another undisclosed arenaviral immunotherapy. Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers.
Development 278
278 
Developing Drug Products with the Label’s Commercial Value in Mind
Camargo
AUGUST 5, 2020
Whether you plan to out-license or commercialize your product, getting the label right matters. The post Developing Drug Products with the Label’s Commercial Value in Mind appeared first on Camargo.
Production 217
217 
Astellas to support development of Taysha’s gene therapy programmes
Pharmaceutical Technology
OCTOBER 25, 2022
Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.
Gene Therapy 264
264 
GSK to license Elsie’s oligonucleotide discovery platform
Pharmaceutical Technology
FEBRUARY 15, 2024
GSK has exercised its option for a licence for Elsie Biotechnologies’ discovery platform to detect and develop new oligonucleotides.
Licensing 240
240 
Biohaven licenses Hangzhou Highlightll’s BHV-8000 to treat brain disorders
Pharmaceutical Technology
MARCH 23, 2023
The deal gives Biohaven global rights for the development of BHV-8000, excluding regions of China. We look forward to advancing BHV-8000 into clinical development and uncovering the potential of neuroimmunomodulation for severe neurological disorders in desperate need of novel treatment options.”
Licensing 263
263 
With Alzheimer's drugs in focus, Bristol Myers rejoins the hunt
Bio Pharma Dive
JUNE 24, 2021
The pharmaceutical giant is spending $80 million for an exclusive license to an experimental drug developed by Prothena.
Licensing 324
324 
Biotech startup pulls in $187M to make ‘multi-payload’ ADCs
Bio Pharma Dive
MARCH 3, 2025
Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.
Licensing 252
252 
Climb Bio enters licensing deal with Mabworks for CLYM116 development
Pharmaceutical Technology
JANUARY 10, 2025
Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising CLYM116.
Licensing 147
147 
RedHill and Hyloris sign agreement for Bekinda’s development
Pharmaceutical Technology
FEBRUARY 26, 2025
RedHill has signed an exclusive licensing agreement with Hyloris for the global development and commercialisation of RHB-102 (Bekinda).
Development 147
147 
Editas, changing course again, looks to partner lead CRISPR therapy
Bio Pharma Dive
OCTOBER 22, 2024
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its clinical-stage treatment reni-cel.
Gene Editing 296
296 
Ablaze Pharmaceuticals to develop drug candidate for liver cancer
Pharmaceutical Technology
APRIL 3, 2023
Ablaze Pharmaceuticals is set to develop a new GPC3-targeted peptide drug candidate for the treatment of liver cancer in China. The company is licensing the first-in-class drug candidate under an existing deal with RayzeBio. The agreement allows Ablaze to clinically develop and commercialise the drug in Greater China.
Development 246
246 
Novo’s latest deal targets cell therapy for diabetes, obesity
Bio Pharma Dive
APRIL 12, 2023
For an upfront payment of $75 million, Novo gets an exclusive license to use Aspect Biosystems’ “bioprinting” technology to develop as many as four treatments for the diseases.
Licensing 320
320 
GreenLight and US NIH partner to develop Covid-19 vaccine for variants
Pharmaceutical Technology
AUGUST 1, 2022
GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.
Vaccine 245
245 
OncoVerity eyes cusatuzumab development in AML after licensing rights
Pharmaceutical Technology
MARCH 28, 2023
On March 27, OncoVerity announced the acquisition of worldwide licensing rights of the anti-CD70 monoclonal antibody cusatuzumab from the biotech argenx. Alongside this, the company closed a $30 million Series A, which came from both argenx and the venture of UCHealth and the University License Equity Holdings.
Licensing 130
130 
XtalPi’s AI biologics discovery platform licensed to Janssen Biotech
Pharmaceutical Technology
OCTOBER 11, 2024
XtalPi's AI biologics discovery platform, XtalFold, has been licensed to Janssen Biotech for advanced biotherapeutics development.
Licensing 130
130 
Vertex pays CRISPR to use its gene editing tech for diabetes drugs
Bio Pharma Dive
MARCH 27, 2023
Vertex will license CRISPR technology to develop insulin-producing islet cells that are more resistant to immune rejection, adding to other efforts directed at Type 1 diabetes.
Gene Editing 296
296 
MSD secures worldwide license for LaNova’s LM-299
Pharmaceutical Technology
NOVEMBER 15, 2024
MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the latter’s new investigational programmed cell death 1 (PD-1)/vascular endothelial growth factor (VEGF) bispecific antibody, LM-299.
Licensing 130
130 
Capsida Biotherapeutics and Prevail to develop CNS gene therapies
Pharmaceutical Technology
JANUARY 5, 2023
Capsida Biotherapeutics and Eli Lilly and Company ’s wholly owned subsidiary Prevail Therapeutics have announced a partnership for the development of non-invasive gene therapies for central nervous system (CNS) diseases. The post Capsida Biotherapeutics and Prevail to develop CNS gene therapies appeared first on Pharmaceutical Technology.
Gene Therapy 237
237 
ReviR Therapeutics partners with Asieris to develop new oncology therapies
Pharmaceutical Technology
FEBRUARY 9, 2023
ReviR Therapeutics has signed a research collaboration and option-to-license agreement with Asieris Pharmaceuticals to discover new oncology therapeutics. Its initial focus is to develop therapeutics in oncology, CNS, and genetically defined disease indications.
Development 241
241 
AbbVie and Simcere Zaiming link to develop trispecific antibody
Pharmaceutical Technology
JANUARY 15, 2025
AbbVie and Simcere Zaiming have announced an option-to-license agreement for the development of an investigational drug candidate, SIM0500.
Development 147
147 
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA
Pharmaceutical Technology
NOVEMBER 5, 2024
Ascendis Pharma will license its TransCon technology to Novo to develop therapies for metabolic and cardiovascular diseases.
Licensing 243
243 
Genezen to license CSL’s lentiviral vector production system
Pharmaceutical Technology
FEBRUARY 21, 2024
Contract development and manufacturing organisation Genezen has announced plans to license CSL’s Cytegrity lentivirus production system.
Licensing 130
130 
In the News: October Regulatory and Development Updates
Camargo
NOVEMBER 11, 2020
Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. for patients with NTRK fusion cancer across all solid tumors.
Development 242
242 
Alteogen signs global license deal with Sandoz
Pharmaceutical Technology
JANUARY 2, 2023
South Korean biotechnology company Alteogen has signed an exclusive license agreement with Swiss company Sandoz to develop and market biosimilar products that are enabled by the former’s Hybrozyme technology. Additionally, the company will have an option to license Alteogen’s Hybrozyme technology for two more products.
Licensing 130
130 
Daiichi Sankyo links up with Korea's Alteogen on subcutaneous Enhertu in $300M licensing deal
Fierce Pharma
NOVEMBER 8, 2024
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be in the works from Korea’s Alteogen following a licensing deal worth up to | Alteogen will use its human hyaluronidase hybridization platform to develop a subcutaneous formulation of the blockbuster antibody-drug conjugate.
Licensing 137
137 
EQRx builds cancer drug pipeline as plans to challenge big pharma take shape
Bio Pharma Dive
OCTOBER 27, 2020
The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy.
Licensing 276
276 
AbbVie licenses FutureGen IBD drug in $1.7bn deal
pharmaphorum
JUNE 13, 2024
AbbVie agrees $1.7bn deal with China's FutureGen to license an anti-TL1A inflammatory bowel disease therapy still in preclinical development
Licensing 114
114 
In the News: July 2021 Regulatory and Development Updates
Camargo
AUGUST 5, 2021
Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. This prospectively developed comparative evidence was used to great advantage by Astellas as RWE in its submission for this new approval.
Development 232
232 
NHS trust bids to take license for abandoned gene therapy
pharmaphorum
APRIL 9, 2024
Great Ormond Street Hospital is applying for the license to a gene therapy for rare disease ADA-SCID that was abandoned by a biotech developer on commercial grounds.
Gene Therapy 119
119 
Editas, in next restructuring step, to sell cell therapy work to Shoreline
Bio Pharma Dive
JANUARY 19, 2023
Shoreline will acquire a preclinical NK cell therapy Editas has been developing, as well as a license to use the CRISPR biotech’s gene editing technology.
Gene Editing 263
263 
Spark Therapeutics partners with SpliceBio for gene therapy
Pharmaceutical Technology
OCTOBER 17, 2023
SpliceBio will license Spark Therapeutics’ propriety protein splicing platform to develop a gene therapy for renal disease.
Gene Therapy 246
246 
Tay Therapeutics and VYNE sign licensing deal for oral BET inhibitor
Pharmaceutical Technology
MAY 3, 2023
Tay Therapeutics, a spin-off firm from the University of Dundee in the UK, has signed a licensing deal with VYNE Therapeutics for the development of its oral bromodomain and extra-terminal domain (BET) inhibitor as a possible treatment for immune-inflammatory and fibrotic disorders.
Licensing 130
130 
Cure Genetics and Frametact seek gene cures for neurological ailments
Pharmaceutical Technology
SEPTEMBER 15, 2023
Cure Genetics has entered a partnership and licensing deal with Frametact to develop gene therapy for familial neurological ailments.
Genetics 246
246 
Lilly partners with AI specialist Insitro to develop metabolic medicines
Bio Pharma Dive
OCTOBER 9, 2024
The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing technology and Lilly eligible for royalties.
Medicine 170
170 
Almirall and EpimAb partner to develop bispecific antibody therapies
Pharmaceutical Technology
OCTOBER 12, 2023
Almirall will license EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop up to three bispecific antibody targets.
Antibody 147
147 
Let's personalize your content